Table 2 Demographics of randomized trial participants
From: Recruitment across two decades of NIH-funded Alzheimer’s disease clinical trials
Donepezil/vitamin E (1999) | NSAIDs (1999) | Simvastatin (2002) | Vitamin B (2003) | Valproate (2003) | Huperzine A (2004) | DHA (2007) | IVIG (2008) | Resveratrol (2012) | INI (2014) | FYN (2014) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Race and ethnicity | |||||||||||
NH White, n (%) | 727 (92.0) | 318 (90.6) | 349 (86.0) | 339 (82.9) | 279 (89.1) | 182 (86.7) | 358 (89.1) | 371 (95.1) | 107 (89.9) | 264 (91.3) | 142 (89.3) |
NH Black, n (%) | 19 (2.4) | 11(3.1) | 27 (6.7) | 36 (8.8) | 16 (5.1) | 14 (6.7) | 23 (5.7) | 6 (1.5) | 7 (5.9) | 8 (2.8) | 7 (4.4) |
NH Asian or Pacific Islander, n (%) | 7 (0.9) | 0 (0.0) | 3 (0.7) | 11 (2.7) | 5 (1.6) | 2 (1.0) | 2 (0.5) | 1 (0.3) | 2 (1.7) | 5 (1.7) | 0 (0.0) |
NH American Indian or Alaskan Native, n (%) | 3 (0.4) | 3 (0.9) | 1 (0.2) | 0 (0.0) | 1 (0.3) | 0 (0.0) | 3 (0.7) | 0 (0.0) | 2 (1.7) | 0 (0.0) | 1 (0.6) |
Hispanic, n (%) | 31 (3.9) | 19 (5.4) | 24 (5.9) | 21 (5.1) | 11 (3.5) | 11 (5.2) | 14 (3.5) | 12 (3.1) | 1 (0.8) | 10 (3.5) | 7 (4.4) |
Others, n (%) | 3 (0.4) | 0 (0.0) | 2 (0.5) | 2 (0.5) | 1 (0.3) | 1 (0.5) | 2 (0.5) | 0 (0.0) | 0 (0.0) | 2 (1.0) | 2 (1.3) |
Age, mean (SD) | 72.9 (7.3) | 73.9 (7.7) | 74.6 (9.3) | 76.9 (8.0) | 76.2 (7.9) | 78.4 (8.0) | 76.0 (8.7) | 70.3 (9.3) | 71.3 (8.1) | 70.9 (7.1) | 71.1 (7.7) |
Sex | |||||||||||
Female, n (%) | 362 (45.8) | 186 (53.0) | 241 (59.4) | 229 (56.0) | 184 (58.8) | 135 (64.3) | 210 (52.2) | 213 (54.6) | 68 (57.1) | 135 (46.7) | 72 (45.3) |
Study partner type | |||||||||||
Spouse, n (%) | 575 (72.8) | 258 (73.5) | 274 (67.5) | 255 (62.3) | 214 (68.4) | 130 (61.9) | 272 (67.7) | NA | 93 (78.2) | 248 (85.8) | 130 (81.8) |
Adult child, n (%) | 113 (14.3) | 71 (20.2) | 102 (25.1) | 121 (29.6) | 74 (23.6) | 67 (31.9) | 104 (25.9) | NA | 17 (14.3) | 23 (8.0) | 18 (11.3) |
Others, n (%) | 102 (12.9) | 22 (6.3) | 30 (7.4) | 33 (8.1) | 25 (8.0) | 13 (6.2) | 26 (6.5) | NA | 9 (7.6) | 18 (6.2) | 11 (6.9) |